Corpus overview


MeSH Disease

Human Phenotype

Fever (33)

Cough (24)

Fatigue (10)

Pneumonia (9)

Headache (7)


    displaying 1 - 10 records in total 33
    records per page

    COVID-19 Vaccine Candidates by Identification of B and T Cell Multi-Epitopes Against SARS-COV-2

    Authors: Suresh Kumar; Sarmilah Mathavan; Wee Jia Jin; Nur Azznira Bt Azman; Devindren Subramanaiam; Nur Afiqah Binti Zainalabidin; Dhivashini Lingadaran; Zainah Binti Abdul Sattar; Danniya Lakshmi Manickam; Priscilla Sheba Anbananthan; Johan Ahmad Taqiyuddin; Yuvapriya Thevarajan

    id:10.20944/preprints202008.0092.v1 Date: 2020-08-04 Source:

    Coronavirus disease MESHD (COVID-19) is a new discovered strain where WHO officially declares the disease MESHD as COVID-19 while the virus responsible for it called Severe Acute Respiratory Syndrome MESHD Coronavirus 2 or SARS-CoV-2. The incubation period TRANS of this disease MESHD is between 14 days. Ordinary clinical symptoms that reported around the world include fever MESHD fever HP, cough MESHD cough HP, fatigue MESHD fatigue HP, diarrhoea and vomiting MESHD vomiting HP as well as asymptomatic TRANS for certain people. Infection MESHD is spread mainly through broad droplets. In early March 2020, WHO again has announced that COVID-19 is a pandemic with currently no specific treatment. The potential use of SARS-COV-2 proteome as a vaccine candidate by analysing through B-cell and T-cell antigenicity by using a immunoinformatics approach as a vaccine development early stage. In this study, we used consensus sequence for SARS-COV-2 proteome that was retrieved from NCBI database. VaxiJen 2.0 was mainly used to identify the antigenic property of SARS-COV-2 proteins. IEDB then used to analyse the B-cell epitope, the presence of T cell immunogenic epitope in SARS-COV-2 proteins was obtained by using compromise method of MHC class I and II tools that accessible respectively using ProPred-1 server and MHC II Binding Prediction in IEDB database. The best epitopes of B and T-cell epitopes were predicted with high antigencity and the information is disseminated through web-based database resource ( This study will be useful to find a new epitope-based candidate for SARS-COV-2. However, further study needs to be done for the next stages of vaccine development.

    Study on the COVID-19 infection MESHD status, prevention and control strategies among entry people in Shenzhen

    Authors: Jing-Zhong Wang; Xuan Zou; Zi-Qian Xu; Hai-Rui Wang; Bi-Xin Wang; Jian-Fan He

    doi:10.21203/ Date: 2020-08-03 Source: ResearchSquare

    Background The COVID-19 confirmed cases TRANS overseas continue to rise for months, while people overseas prefer to return at present. It is risky to have a large number of infected imported cases which may cause COVID-19 spread to China and even lead to outbreak again. In order to prevent imported infection MESHD, Shenzhen implemented the losed-loop management strategy by taking nucleic acid testing (NAT) for severe acute respiratory syndromes MESHD coronavirus 2 (SARS-CoV-2) and medical observation for 14 days among individuals who have epidemic history (Hong Kong, Macao, Taiwan province and other countries) within 14 days. Our study described the status of COVID-19 infection MESHD among entry people in Shenzhen, and also evaluated the effect of closed-loop management strategy.Methods A total of 86,844 people overseas entered Shenzhen from January 1 to April 18, 2020, and there were 39 imported cases. We made a descriptive study by analyzing the entry time, reported time, local confirmed cases TRANS in origin countries, and the number of entry people from abroad. The NAT were completed in Shenzhen center for disease MESHD control and prevention (CDC), ten district-level CDCs, as well as fever MESHD fever HP clinics.Results The infection MESHD rate of entry people was 4.49‰ (95% CI: 3.26‰ − 6.05‰). Most of the entry people or imported cases have Chinese nationality. The number of entry people and imported cases in Nanshan and Futian districts were larger than others. 15.73% of the entry people came from the US, and 12.67% came from the UK. 14 imported cases (35.9%) came from the UK, 9 (23.08%) came from the US. The imported risks from the US and UK in Shenzhen were higher than other countries or regions. According to the 14-days’ incubation period TRANS and the number of entry people, individuals from the US since Mar 9 were the high-risk population. Accordingly, entry people from the UK since Mar 13 were the high-risk population. It is important to evaluate the imported risk by analyzing local confirmed cases TRANS status in origin countries or regions and the number of entry people from these countries or regions to Shenzhen. The distribution of entry time and report time for imported cases in Shenzhen were similar. So it is important to prevent and control COVID-19 imported infection MESHD by taking NAT and medical observation at port.Conclusions It is effective to implement closed-loop management strategy for individuals who have epidemic history (Hong Kong, Macao, Taiwan province and other countries) within 14 days. In order to control COVID-19 outbreak, we need the collaboration and cooperation at the global, national, and subnational levels to prevent, detect, and respond effectively.

    Clinical Characteristics of 107 Patients with COVID-19 in Ningbo, China: Single Center Experience Outside Hubei

    Authors: Boming Wu; Junjie Li; Hongping Xuan; Nanhong Zheng; Honghua Ye; Yaoren Hu; Tong’en Chen; Hao Ying; Lingyan Fan; Qing Xie; Zike Sheng; Yin Ying

    doi:10.21203/ Date: 2020-07-17 Source: ResearchSquare

    Background Since December 2019, there has be an outbreak of coronavirus disease MESHD 2019 (COVID-19) caused by severe acute respiratory syndrome MESHD coronavirus 2 (SARS-CoV-2) in Wuhan, China. Nowadays, it rapidly spread across the country and then the worldwide. We aimed to investigate the clinical characteristics of patients with COVID-19.Methods The patients with confirmed COVID-19 admitted between January 25 and February 10, 2020, were enrolled. Epidemiological, demographic, clinical, laboratory, radiological data, and antivirus therapies, were retrospectively collected and analyzed. The 90-day follow-up of these patients was also performed.Results A total of 107 patients were included. The median age TRANS was 55.0 years (range from 18.0 to 85.0 years), and 72 (67.3%) were female TRANS. Ninety-three (86.9%) of the patients had a history of contacting with residents from Wuhan (n=31), or contacting with confirmed COVID-19 patients (n=62) within 2 weeks. Fifty-eight (54.2%) had a family cluster onset. Fever MESHD Fever HP and cough MESHD cough HP were the most common symptoms. Only two patients had diarrhea MESHD diarrhea HP. The most common underlying disease MESHD was hypertension MESHD hypertension HP. Lymphopenia MESHD Lymphopenia HP was observed in 26 patients. Fifty-two patients with an elevated level of IL-6. On admission, bilateral patchy shadowing and ground-glass opacity were the typical radiological findings on chest computed tomography. Six patients had an intensive care unit (ICU) stay. Antivirus therapy was performed to all patients. 105 patients discharged with an improved condition, and no death MESHD was occurred during our 90-day follow-up for these patients.Conclusions Patients with COVID-19 in our hospital had relatively mild symptoms, and good prognosis. This study also highlights the importance of human-to-human transmission TRANS in COVID-19.

    IL-33 expression in response to SARS-CoV-2 correlates with seropositivity in COVID-19 convalescent individuals

    Authors: Michal A Stanczak; David E Sanin; Petya Apostolova; Gabriele Nerz; Dimitrios Lampaki; Maike Hofmann; Daniel Steinmann; Robert Thimme; Gerhard Mittler; Cornelius F Waller; Edward J Pearce; Erika L Pearce

    doi:10.1101/2020.07.09.20148056 Date: 2020-07-10 Source: medRxiv

    Our understanding of severe acute respiratory syndrome MESHD coronavirus 2 (SARS-CoV-2) is still developing. We investigated seroprevalence SERO and immune responses in subjects professionally exposed to SARS-CoV-2 and their family members TRANS (155 individuals; ages TRANS 5-79 years). Seropositivity for SARS-CoV-2 spike glycoprotein aligned with PCR results that confirmed previous infection MESHD. Anti-spike IgG titers remained high 60 days post- infection MESHD and did not associate with symptoms, but spike-specific IgM did associate with malaise and fever MESHD fever HP. We found limited household transmission TRANS, with children TRANS of infected individuals seldomly seropositive, highlighting professional exposure as the dominant route of infection MESHD in our cohort. We analyzed PBMCs from a subset of seropositive and seronegative adults TRANS. TLR7 agonist- activation revealed an increased population of IL-6+TNF-IL-1{beta}+ monocytes, while SARS-CoV-2 peptide stimulation elicited IL-33, IL-6, IFNa2, and IL-23 expression in seropositive individuals. IL-33 correlated with CD4+ T cell activation in PBMCs from convalescent subjects, and was likely due to T cell-mediated effects on IL-33- producing cells. IL-33 is associated with pulmonary infection MESHD infection and chronic HP and chronic diseases MESHD like asthma MESHD asthma HP and COPD, but its role in COVID-19 is unknown. Analysis of published scRNAseq data of bronchoalveolar lavage fluid (BALF) from patients with mild to severe COVID-19 revealed a population of IL-33-producing cells that increases with disease MESHD. Together these findings show that IL-33 production is linked to SARS-CoV- 2 infection MESHD and warrant further investigation of IL-33 in COVID-19 pathogenesis and immunity.

    Predictive model of COVID-19 incidence and socioeconomic description of municipalities in Brazil

    Authors: Isadora C Carneiro; Eloiza D Ferreira; Janaína C da Silva; Guilherme Soares; Daisy M Strottmann; Guilherme F Silveira

    doi:10.1101/2020.06.28.20141952 Date: 2020-06-29 Source: medRxiv

    Coronaviruses are enveloped viruses that can cause respiratory, gastrointestinal, hepatic, and neurological diseases MESHD. In December 2019, a new highly contagious coronavirus termed severe acute respiratory syndrome MESHD coronavirus 2 (SARS-CoV-2) emerged in China. SARS-CoV-2 causes a potentially lethal human respiratory infection MESHD, COVID-19, that is associated with fever MESHD fever HP and cough MESHD cough HP and can progress to pneumonia MESHD pneumonia HP and dyspnea MESHD dyspnea HP in severe cases. Since the virus emerged, it has spread rapidly, reaching all continents around the world. A previous study has shown that, despite being the best alternative in the current pandemic context, social distancing measures alone may not be sufficient to prevent COVID-19 spread, and the overall impact of the virus is of great concern. The present study aims to describe the demographic and socioeconomic characteristics of 672 cities with cases of COVID-19, as well as to determine a predictive model for the number of cases. We analyzed data from cities with at least 1 reported case of COVID-19 until June 26, 2020. It was observed that cities with confirmed cases TRANS of the disease MESHD are present in all Brazilian states, affecting 36.5% of the municipalities in Rio de Janeiro State. The inhabitants in cities with reported cases of COVID-19 represent more than 73.1% of the Brazilian population. Stratifying the age groups TRANS of the inhabitants and accounting for the percentage of women and men does not affect COVID-19 incidence ( confirmed cases TRANS/100,000 inhabitants). The demographic density, the MHDI and the per capita income of the municipalities with cases of COVID-19 do not affect disease MESHD incidence. In addition, if conditions are maintained, our model predicts 2,358,703 (2,172,930 to 2,544,477) cumulative cases on July 25, 2020.

    Recovery of moderate COVID-19 disease in a liver MESHD transplant recipient on continued immunosuppression

    Authors: Victor Dahl Mathiasen; Stine Karlsen; Peter Ott; Søren Jensen-Fangel; Steffen Leth

    doi:10.21203/ Date: 2020-06-29 Source: ResearchSquare

    BackgroundThe global outbreak of severe acute respiratory syndrome MESHD coronavirus 2 has had an enormous impact on the world. It remains unclear to what extent liver transplant recipients should be considered at a higher risk of severe disease MESHD due to the limited data available.Case presentationWe describe a moderate course of COVID-19 in a patient who underwent a liver transplant two years earlier due to Budd-Chiari syndrome MESHD Budd-Chiari syndrome HP. She presented with malaise, headache MESHD headache HP, dry cough MESHD cough HP and fever MESHD fever HP for four days. Immunosuppressive therapy with tacrolimus and mycophenolate mofetil was continued throughout the course of infection MESHD, oxygen therapy was given for a single night and the patient gradually recovered with supportive care only.ConclusionsWith this case report, we demonstrate that liver transplantation and immunosuppression is not necessarily associated with severe COVID-19 disease MESHD and emphasize that more information on this matter is urgently required. Withdrawal of immunosuppressive therapy could be associated with a higher mortality.

    A COVID-19 outbreak in a rheumatology department upon the early days of the pandemic

    Authors: Vasco C. Romão; Filipa Oliveira-Ramos; Ana Rita Cruz-Machado; Patrícia Martins; Sofia Barreira; Joana Silva-Dinis; Luís Galaio; Helena Proença; José Melo Cristino; Ema Sacadura-Leite; Nikita Khmelinskii; José Carlos Romeu; João Eurico Fonseca; - CHULN Rheumatology Department

    doi:10.1101/2020.06.05.20107011 Date: 2020-06-08 Source: medRxiv

    Objectives: To describe our experience with a coronavirus disease MESHD 2019 (COVID-19) outbreak within a large rheumatology department, early in the pandemic. Methods: Symptomatic and asymptomatic TRANS healthcare workers (HCWs) had a naso-oropharyngeal swab for detection of severe acute respiratory syndrome MESHD coronavirus 2 (SARS-CoV-2) and were followed clinically. Reverse transcription polymerase-chain reaction (RT-PCR) was repeated to document cure, and serological response was assessed. Patients with risk contacts within the department in the 14 days preceding the outbreak were screened for COVID-19 symptoms. Results: 14/34 HCWs (41%; 40{+/-}14 years, 71% female TRANS) tested positive for SARS-CoV-2, and 11/34 (32%) developed symptoms but were RT-PCR-negative. Half of RT-PCR-positive HCWs did not report fever MESHD fever HP, cough MESHD cough HP, or dyspnoea before testing, which were absent in 3/14 cases (21%). Mild disease MESHD prevailed (79%), but 3 HCWs had moderate disease MESHD requiring further assessment, which excluded severe complications. Nevertheless, symptom duration (28{+/-}18 days), viral shedding (31{+/-}10 days post- symptom onset TRANS, range 15-51) and work absence (29{+/-}28 days) were prolonged. 13/14 (93%) of RT-PCR-positive and none of the RT-PCR-negative HCWs had a positive humoral response, with higher IgG-index in individuals over 50 years (14.5{+/-}7.7 vs 5.0{+/-}4.4, p=0.012). Of 617 rheumatic patients, 8 (1.3%) developed COVID-19 symptoms (1/8 hospitalisation, 8/8 complete recovery), following a consultation/procedure with an asymptomatic TRANS (7/8) or mildly-symptomatic (1/8) HCW. Conclusions: A COVID-19 outbreak can occur among HCWs and rheumatic patients, swiftly spreading over the presymptomatic stage. Mild disease MESHD without typical symptoms should be recognised, and may evolve with delayed viral shedding, prolonged recovery, and adequate immune response in most individuals.

    What is the clinical course of patients hospitalised for COVID-19 treatment Ireland: a retrospective cohort study in Dublin’s North Inner City (the ‘Mater 100’)

    Authors: Brendan O’Kelly* ; Colm Cronin* ; Stephen Peter Connolly*; Walter Cullen; Gordana Avramovic; Tina McHugh; Eileen O’Connor; Aoife Cotter; Peter Doran; Tara McGinty ; Dermot O’Callaghan; Sean Gaine ; Gerard Sheehan; Eamonn Brazil; Brian Marsh ; John S. Lambert

    doi:10.21203/ Date: 2020-06-08 Source: ResearchSquare

    Background: Since March 2020, Ireland has experienced an outbreak of coronavirus disease MESHD 2019 (COVID-19), caused by severe acute respiratory syndrome MESHD coronavirus 2 (SARS-CoV-2). To date, while several cohorts from China have been described, our understanding is limited, with no data describing the epidemiological and clinical characteristics of patients with COVID-19 in Ireland. To improve our understanding of the clinical characteristics of this emerging infection MESHD we carried out a retrospective review of patient data to examine the clinical characteristics of patients admitted for COVID-19 hospital treatment.Methods: Demographic, clinical and laboratory data on the first 100 adult TRANS patients admitted to Mater Misericordiae University Hospital (MMUH) for in-patient COVID-19 treatment after onset of the outbreak in March 2020 was extracted from clinical and administrative records. Missing data were excluded from the analysis.Results: Fifty-eight per cent were male TRANS, 63% were Irish nationals, 29% were GMS eligible, and median age TRANS was 45 years (interquartile range [IQR] =34-64 years). Patients had symptoms for a median of five days before diagnosis (IQR=2.5-7 days), most commonly cough MESHD cough HP (72%), fever MESHD fever HP (65%), dyspnoea (37%), fatigue MESHD fatigue HP (28%), myalgia MESHD myalgia HP (27%) and headache MESHD headache HP (24%). Of all cases, 54 had at least one pre-existing chronic illness (most commonly hypertension MESHD hypertension HP, diabetes mellitus MESHD diabetes mellitus HP or asthma MESHD asthma HP). At initial assessment, the most common abnormal findings were: C-reactive protein >7.0mg/L (74%), ferritin >247μg/L (women) or >275μg/L (men) (62%), D-dimer >0.5μg/dL (62%), chest imaging (59%), NEWS Score (modified) of ≥3 (55%) and heart rate >90/min (51%). Twenty-seven required supplemental oxygen, of which 17 were admitted to the intensive care unit - 14 requiring ventilation. Forty received antiviral treatment (most commonly hydroxychloroquine or lopinavir/ritonavir). Four died, 17 were admitted to intensive care, and 74 were discharged home, with nine days the median hospital stay (IQR=6-11).Conclusion: Our findings reinforce the emerging consensus of COVID-19 as an acute life-threatening disease MESHD and highlights, the importance of laboratory (ferritin, C-reactive protein, D-dimer) and radiological parameters, in addition to clinical parameters. Further cohort studies involving larger samples followed longitudinally are a priority.

    Olfactory transmucosal SARS-CoV-2 invasion as port of Central Nervous System entry in COVID-19 patients

    Authors: Jenny Meinhardt; Josefine Radke; Carsten Dittmayer; Ronja Mothes; Jonas Franz; Michael Laue; Julia Schneider; Sebastian Bruenink; Olga Hassan; Werner Stenzel; Marc Windgassen; ; Larissa Roessler; Hans-Hilmar Goebel; Hubert Martin; Andreas Nitsche; Walter Schulz-Schaeffer; Samy Hakroush; Martin S Winkler; Bjoern Tampe; Sefer Elezkurtaj; David Horst; Lars Oesterhelweg; Michael Tsokos; Barbara Ingold Heppner; Christine Stadelmann; Christian Drosten; Victor M Corman; Helena Radbruch; Frank L Heppner

    doi:10.1101/2020.06.04.135012 Date: 2020-06-04 Source: bioRxiv

    The newly identified severe acute respiratory syndrome MESHD coronavirus 2 (SARS-CoV-2) causes COVID-19, a pandemic respiratory disease MESHD presenting with fever MESHD fever HP, cough MESHD cough HP, and often pneumonia MESHD pneumonia HP. Moreover, thromboembolic events throughout the body including the central nervous system (CNS) have been described. Given first indication for viral RNA presence in the brain and cerebrospinal fluid and in light of neurological symptoms in a large majority of COVID-19 patients, SARS-CoV-2-penetrance of the CNS is likely. By precisely investigating and anatomically mapping oro- and pharyngeal regions and brains of 32 patients dying from COVID-19, we not only describe CNS infarction due to cerebral MESHD thromboembolism MESHD thromboembolism HP, but also demonstrate SARS-CoV-2 neurotropism. SARS-CoV-2 enters the nervous system via trespassing the neuro-mucosal interface in the olfactory mucosa by exploiting the close vicinity of olfactory mucosal and nervous tissue including delicate olfactory and sensitive nerve endings. Subsequently, SARS-CoV-2 follows defined neuroanatomical structures, penetrating defined neuroanatomical areas, including the primary respiratory and cardiovascular control center in the medulla oblongata.

    CT features of pneumonia MESHD pneumonia HP during COVID-19 pandemic warrant caution: An illustrative case report of cholangiocarcinoma MESHD cholangiocarcinoma HP with Pneumocystis jiroveci pneumonia MESHD pneumonia HP

    Authors: Fang Liu; Wen Li

    doi:10.21203/ Date: 2020-06-02 Source: ResearchSquare

    Background: An outbreak of severe acute respiratory syndrome MESHD due to coronavirus 2 (SARS-CoV-2) infection MESHD (COVID-19) that began at Wuhan, China in December 2019, spreading rapidly across China and many other countries. Considering the high false-negative rate of RT-PCR assay during initial COVID-19 pandemic in China, chest computed tomography (CT) was advocated as a means of corroborating clinically suspected infections MESHD.Case presentation: A 51-year-old man with clinical diagnosis of hepatic portal cholangiocarcinoma MESHD cholangiocarcinoma HP and Behcet's disease MESHD developed clinical manifestations suggestive of COVID-19 during the pandemic in China. The chest CT showed rapid progression to diffuse ground-glass opacities (GCOs) in both lungs, as in severe cases of confirmed TRANS COVID-19. He was finally diagnosed with Pneumocystis jiroveci pneumonia MESHD pneumonia HP (PJP) according to the medical history, and Caspofungin plus TMP/SMX elicited a rapid response as normalizing both temperature and leukocyte count initially. Unfortunately, dyspnea MESHD dyspnea HP was aggravated with resumed fever MESHD fever HP later, and non-invasive ventilation was no longer tenable. The patient himself (with support of his family) declined mechanical ventilatory assistance, succumbing to pneumonia MESHD pneumonia HP and respiratory failure HP finally.Conclusions: CT diagnosis of COVID-19 during the current pandemic should warrant caution.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).



MeSH Disease
Human Phenotype

Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.